EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY

Clapton Dias,Adam Shaywitz,Blaire Cooke,Stephen Uy,Maurice Emery,John P. Gibbs,Caroline Crispino,Karen Smirnakis,Brian Smith,Bing Gao,Scott M. Wasserman,Evan A. Stein

EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY

2012

Clapton Dias
Adam Shaywitz
Blaire Cooke
Stephen Uy
Maurice Emery
John P. Gibbs
Caroline Crispino
Karen Smirnakis
Brian Smith
Bing Gao
Scott M. Wasserman
Evan A. Stein

Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates surface expression of the low density lipoprotein (LDL) receptor (LDL-R), increasing circulating LDL cholesterol (LDL-C). Statins increase LDL-R and PCSK9 levels. AMG 145, a fully human monoclonal antibody against PCSK9, has been

Keywords:

Low-density lipoprotein
Kexin
Cholesterol
Immunology
Proprotein convertase
Diabetes mellitus
PCSK9
Internal medicine
Cardiology
Receptor
Medicine
Endocrinology
Monoclonal antibody
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations